Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIGB-300 for recurrent and non-recurrent genital condyloma
ISRCTN86355789Phase 3Completed
- Sponsor
- Laboratorio Elea
- Start
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised trial of cigb-300 in anogenital warts (3 arms), sponsored by Laboratorio Elea. Primary endpoints: Safety of perilesional CIGB-300 and Overall efficacy on lesion resolution and recurrence. Started Jun 2010; status: completed.
02
Drugs
cigb-300
03
Conditions
anogenital warts
Beyond the preview
Go deeper on ISRCTN86355789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86355789.